Navigation Links
Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Date:1/3/2012

SAN DIEGO, Jan. 3, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 9, 2012 at 5:00 p.m. ET / 2:00 p.m. PT. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview.

The presentation and break-out session will be webcast through the "Investors" section of Amylin's corporate website at www.amylin.com, and a recording will be made available following the event. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California and has a commercial manufacturing facility in Ohio. Further information about Amylin Pharmaceuticals is available at www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amylin and Lilly Set Date and Time for Conference Call
2. Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA
3. Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences
4. Amylin Pharmaceuticals to Webcast Third Quarter Results
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
7. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
8. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
9. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
10. Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
11. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/15/2019)... ... October 14, 2019 , ... ARPR , an award-winning tech PR agency at ... as a Health Care Agency of the Year in the Ragan’s Health Care PR ... a finalist by Ragan’s. The firm also revealed today that its healthIT practice group grew ...
(Date:10/10/2019)... ... October 10, 2019 , ... R3 Stem Cell announces it has added an ... 2019 in Las Vegas with spots still open. , The speaker, Dr. Ian White ... League universities including Cornell, Harvard and Dartmouth. He currently serves as the Chief Scientific ...
(Date:10/8/2019)... ... 07, 2019 , ... Erchonia Corporation, the global leader in ... that the U.S. Food and Drug Administration (FDA) has granted the company 510(k) ... of chronic neck and shoulder pain of musculoskeletal origin. , Erchonia continues to ...
(Date:10/3/2019)... ... , ... Cheyenne is a beautiful and strong Quarter Horse and a huge ... Rebel’s Run , which offers riding lessons and trail riding in Afton, Virginia. ... Mimi describes her as her “go to horse.” Thus, you can imagine the ...
Breaking Biology Technology:
(Date:10/26/2019)... ... October 23, 2019 , ... Medrio is pleased ... its executive leadership team. , As a market leader in solutions for EDC, ... pharma companies to reduce timelines and improve quality with real-time data capture. ...
(Date:10/26/2019)... , ... October 24, 2019 , ... THE PRINCESS VEST, ... been the standard choice for female providers, they were the only choice. Women in ... breasts, or a loose garment that can allow harmful radiation to penetrate the sides ...
(Date:10/22/2019)... ... ... Join QPS experts Dawn Moore, Director of Preclinical Business Development ... on Thursday, October 31, 2019 at 11am EDT (3pm GMT/UK) to find out what ... expertise in method development, which can be evaluated through incurred sample reanalysis. Incurred sample ...
Breaking Biology News(10 mins):